Merck licenses antidepressant candidate to Cerecor

04/22/2013 | Pharmaceutical Business Review Online

Merck & Co. granted Cerecor exclusive global rights to develop and market the experimental drug MK-0657, a small molecule NMDA receptor subunit 2B antagonist for all clinical indications. Cerecor plans to develop the compound as a treatment for severe refractory depression and suicidal thoughts and behavior. The deal entitles Merck to milestone fees and royalties.

View Full Article in:

Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY